检索

期
标题
作者
卷 14, 编号 1 (2017)
Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
Maksimov M., Dralova O.
PDF
(Rus)
卷 13, 编号 3 (2016)
Combined pharmacotherapy of arterial hypertension. Overview fixed combination antihypertensive drugs
Morozova T., Andrushchishina T., Yudina I.
PDF
(Rus)
卷 10, 编号 4 (2013)
Place of angiotensin receptor blockers in the treatment of hypertension according to the latest recommendations of the 2013 European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) for the treatment of hypertension
Chukaeva I., Solovieva M., Litvinova S.
卷 12, 编号 4 (2015)
«New» molecules composed of rational combinations of antihypertensive drugs: issues of choice
Kislyak O., Chervyakova Y.
PDF
(Rus)
卷 10, 编号 2 (2013)
Efficacy of irbesartan in arterial hypertension and metabolic syndrome
Ostroumova O., Zykova A., Polosova T., Bondarets O.
卷 16, 编号 3 (2019)
The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus
Zhernakova J., Chazova I., Blinova N.
PDF
(Rus)
卷 10, 编号 2 (2013)
Sartans in the treatment of high-risk hypertension: the abilities of candesartan
Morozova T.
卷 6, 编号 4 (2009)
Rationale for the use of sartans in patients with arterial hypertension
Stryuk R.
卷 12, 编号 2 (2015)
The hardness of the vessel wall in patients with arterial hypertension
Ostroumova O., Kochetkov A., Kopchenov I., Guseva T., Bondarec O.
PDF
(Rus)
卷 10, 编号 1 (2013)
Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer
Gilyarevsky S., Orlov V., Kuzmina I., Golshmid M.
卷 15, 编号 3 (2018)
The progression of carotid vascular remodeling risk factors in patients with arterial hypertension
Pavlova O., Korobko I., Nechesova T., Liventseva M., Zatoloka N., Kovsh E., Ogurtsova S., Mrochek A.
PDF
(Rus)
卷 11, 编号 3 (2014)
The combination therapy in arterial hypertension: opportunities of the fixed combination of irbesartan andhydrochlorothiazide(Koaprovel’)
Ostroumova O., Guseva T., Bondarets O.
PDF
(Rus)
卷 6, 编号 2 (2009)
Perspectives of using angiotensin receptor antagonists
Fomin V.
卷 14, 编号 2 (2017)
Advantages azilsartan medoxomil in patients with arterial hypertension: how to make a choice and to optimize antihypertensive therapy?
Martynyuk T., Chazova I.
PDF
(Rus)
卷 11, 编号 3 (2014)
Possibilities ARB II (sartans) in hypertensive patients
Morozova T., Andrushchishina T., Gontarenko S.
PDF
(Rus)
卷 6, 编号 2 (2009)
Sartans in cardiological practice: new possibilities in therapy of cardiovascular diseases
Smolenskaya O.
卷 11, 编号 2 (2014)
The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience
Gilyarevsky S.
PDF
(Rus)
卷 13, 编号 4 (2016)
The choice of antihypertensive therapy in correction of cognitive impairments and prevention of dementia: possibilities of valsartan and fixed-dose combination of valsartan and hydrochlorothiazide
Ostroumova O., Garelik I., Karavashkina E.
PDF
(Rus)
卷 11, 编号 1 (2014)
Place of angiotensin receptor blockers in antihypertensive therapy
Martynov A., Urlaeva I., Akatova E., Nikolin O.
PDF
(Rus)
1 - 19 的 19 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##